Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib-Reference-Cited by-同舟云学术

Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib

Published:2006-09-20 Issue:27 Volume:24 Page:4517-4520
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Jackman David M.¹,Holmes Alison J.²,Lindeman Neal³,Wen Patrick Y.⁴,Kesari Santosh⁴,Borras Ana M.⁵,Bailey Christopher⁶,de Jong Francisca⁷,Jänne Pasi A.¹,Johnson Bruce E.¹

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

3. Department of Pathology, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA

4. Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Neurology, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA

5. Translational Research Laboratory, Dana-Farber Cancer Institute, Boston, MA

6. Department of Drug Metabolism and Pharmokinetics, AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom

7. Analytico Medinet BV, Breda, the Netherlands

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.06.6126

Reference10 articles.

1. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2. Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations